A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

BACKGROUND: Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor complex that prevents and displaces binding of Aβ oligomers to neurons. By stopping a key initiating event in Alzheimer's disease, this first-in–class drug candidate mitigates downstream synaptotoxicity and res...

Descripción completa

Detalles Bibliográficos
Autores principales: Grundman, Michael, Morgan, Roger, Lickliter, Jason D., Schneider, Lon S., DeKosky, Steven, Izzo, Nicholas J., Guttendorf, Robert, Higgin, Michelle, Pribyl, Julie, Mozzoni, Kelsie, Safferstein, Hank, Catalano, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352291/
https://www.ncbi.nlm.nih.gov/pubmed/30723776
http://dx.doi.org/10.1016/j.trci.2018.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352291/
https://www.ncbi.nlm.nih.gov/pubmed/30723776
http://dx.doi.org/10.1016/j.trci.2018.11.001

Ejemplares similares